Although BioAgilytix’s team members come from a diverse range of backgrounds, we are all united by a shared passion for scientific excellence, which is the standard we...
By PD Dr. Arno Kromminga
Gene therapy has come a long way since it was first suggested as a potential treatment for genetic-based diseases in 1972. Completion of the ...
On May 24, the U.S. Food and Drug Administration (FDA) approved onasemnogene abeparvovec-xioi (Zolgensma), the first gene therapy for pediatric patients with the most...
We look forward to attending the annual WRIB conference every year – it is a staple event for our industry and provides an invaluable opportunity to collaborate with...
Gene therapy has experienced an exciting resurgence in the post-genomic era, with the efficacy and safety of this class of drugs now proving out and culminating most...
The rise of precision medicine has brought with it unprecedented breakthroughs in biologic drug development, particularly related to immunotherapy. These novel...
You may have seen that in January, the FDA released new guidance designed to facilitate the development and validation of assays for the detection of anti-drug...
Oxford Global’s Annual Biomarkers Congress is an event that we mark on our calendars every year. The lively discussions surrounding key opportunities and challenges in...
Gene therapy is experiencing an exciting resurgence with the development of new genome editing tools and new gene delivery vectors. Approximately 60% of gene therapy...
In the last two decades, our understanding of the mechanisms behind human disease paired with significant innovation in complementary technologies has empowered our...